Pivotal readout

Beam's base-edited risto-cel hits main goal in sickle cell study, BLA eyed for year-end

At a prespecified interim look, the BEACON trial of BEAM-101 met its efficacy endpoint of at least 12 months without severe vaso-occlusive crises and all safety endpoints; response rates were not disclosed. Of 49 treated patients, 31 had enough follow-up. Beam aims to file a US biologics application as soon as the end of 2026.

Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call